English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Pharma & Biotech BioTech
글로벌데이터의 새로운 보고서 아시아태평양 지역, 글로벌 임상 시험의 50 % 유치
Sep 06, 2022 07:00 HKT
Novotech参加2022年ESMO大会 - 新数据显示亚太地区的肿瘤学试验增长100%
Sep 06, 2022 07:00 HKT
Novotech參加2022年ESMO大會 - 新數據顯示亞太地區的腫瘤學試驗增長100%
Sep 06, 2022 07:00 HKT
Dammam Valley to acquire majority in Arcensus GmbH; accelerating Whole Genome Sequencing in genetic diagnostics, delivering breakthrough technologies in genomic bioinformatics
Sep 05, 2022 20:00 HKT
Novotech at ESMO Congress 2022 - New Data Shows 100% Oncology Trials Growth in APAC
Sep 05, 2022 18:00 HKT
亚太地区吸引了50%的全球临床试验 根据新的GlobalData报告
Sep 02, 2022 21:00 HKT
亞太地區吸引了50%的全球臨床試驗 根據新的GlobalData報告
Sep 02, 2022 21:00 HKT
医思健康主席邓志辉增持公司股份 对集团业务未来发展态势维持信心
Sep 02, 2022 17:33 HKT
醫思健康主席鄧志輝增持公司股份 對集團業務未來發展態勢維持信心
Sep 02, 2022 17:32 HKT
EC Healthcare Chairman Mr. Eddy Tang Increases Shareholding, Demonstrating Full Confidence in the Group's Future Development
Sep 02, 2022 17:31 HKT
Legend Capital: The Logic of Technology Investment Has Changed
Sep 02, 2022 17:05 HKT
Younger Colorectal Cancer Population Highlights the Importance of Early Screening, Highly Sensitive Test Product Prenetics has Launched the Market
Sep 02, 2022 14:33 HKT
APAC Attracts 50% of Global Clinical Trials According to New GlobalData Report
Sep 02, 2022 14:00 HKT
百奥赛图今日登陆港交所 硬核技术打通新药研发全链条
Sep 02, 2022 13:41 HKT
百奧賽圖今日登陸港交所 硬核技術打通新藥研發全鏈條
Sep 02, 2022 13:40 HKT
CT Event Asia to host ASEAN Healthcare Transformation Summit 2022
Sep 01, 2022 15:50 HKT
百奥赛图今日上市:专注新药技术创新 “千鼠万抗”发展潜力巨大
Sep 01, 2022 14:23 HKT
百奧賽圖今日上市:專注新藥技術創新 「千鼠萬抗」發展潛力巨大
Sep 01, 2022 14:22 HKT
Transcenta Holding (06628): Product pipeline progressing well with significant competitive differentiation
Sep 01, 2022 10:31 HKT
金活醫藥集團持續聚焦主業發展 2022年中期業績穩中向好
Aug 31, 2022 22:30 HKT
<< Previous  Next >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: